Oncology Programs

About Laigo Bio

Laigo Bio is an early-stage biotech developing a novel targeted protein degradation platform called SureTACs (Surface Removal Targeting Chimeras). The technology uses bispecific antibodies to bring disease-causing membrane proteins into proximity with specific E3 ligases, marking them for lysosomal destruction. The company has raised €17 million in seed financing to advance its preclinical oncology and auto-immunity programs and is exploring strategic partnerships. Laigo's approach aims to tackle traditionally 'undruggable' targets with high tissue specificity.

About Peter Biotherapeutics

Peter Biotherapeutics is a private, preclinical-stage biotech founded in 2020, developing next-generation gene-editing therapies. Its flagship platform, RITDM™ 2.0, is a novel gene-editing technology that avoids creating double-strand DNA breaks and uses no bacterial or viral components, potentially offering a superior safety profile and enabling repeat dosing. The company is initially targeting genetic diseases such as metabolic disorders, sickle cell disease, and Duchenne Muscular Dystrophy, as well as oncology, leveraging a leadership team and scientific advisory board with deep expertise in genetics and drug development.

About Ciloa Bio

Ciloa Bio is a private, preclinical-stage biotech founded in 2016 and based in Montpellier, France. The company has developed a proprietary platform, EVENGI, for engineering small extracellular vesicles (sEVs) to carry therapeutic payloads, with a lead program (APN-sEVs) targeting obesity and type 2 diabetes. Ciloa has secured significant non-dilutive funding, including a recent €6.5 million grant from France 2030, and engages in strategic partnerships to advance its pipeline in metabolic diseases, vaccines, and oncology.

About Vyripharm Biopharmaceuticals

Vyripharm Biopharmaceuticals is a private, pre-revenue biotech company founded in 2015, operating from the Texas Medical Center in Houston. The company is developing a novel, integrated theranostic platform (BioSync™) that combines diagnostics and therapeutics, with applications in oncology, viral infections like COVID-19, and neurological disorders. Its strategy involves building global partnerships and leveraging AI, but it faces significant risks as an early-stage company with a broad, complex pipeline and unproven technology. Key leadership includes individuals with backgrounds in academia, business development, and medicine.

About Allinky Biopharma

Allinky Biopharma is a private, preclinical-stage biotech pioneering novel oral allosteric inhibitors for chronic inflammation and cancer. Its core innovation is a first-in-class oral inhibitor targeting the production of IL-1β, a key inflammatory mediator, with significant patents granted in the US, Europe, and China. The company is backed by venture capital and non-dilutive grants, having recently secured a €2M capital increase and a Seal of Excellence from the EU's EIC Accelerator, positioning it to advance its lead candidate towards clinical trials.

About Engine Biosciences

Engine Biosciences is a private, pre-clinical stage biotech founded in 2015, leveraging a proprietary platform combining machine learning algorithms and large-scale combinatorial CRISPR screening to map disease biology and discover novel drug targets and biomarkers. The company is advancing a pipeline focused on targeted therapies for solid tumors and collaborates with partners in other therapeutic areas. Backed by a seasoned leadership team and prominent investors, Engine aims to translate deep biological insights into impactful precision medicines.

About OyaGen

OyaGen is a privately held, preclinical-stage biotechnology company founded in 2003 with a dual focus on proprietary drug discovery and contract research services. Its core pipeline targets viral infections, including HIV, Ebola, and coronaviruses, with a platform aimed at disabling key viral proteins. The company operates from a state-of-the-art lab in the Rochester BioVenture Center and is seeking significant capital to advance its lead HIV candidate into clinical trials while exploring strategic partnerships or M&A.

About Terns Pharmaceuticals

Terns Pharmaceuticals is a publicly traded, clinical-stage biotech company with a mission to advance transformative medicines by reimagining known biology. Its core strategy involves selecting de-risked, clinically validated targets and applying innovative medicinal chemistry to develop potentially best-in-class small-molecule drugs. The company's most significant achievement is the advancement of TERN-701 for CML, which has culminated in a definitive acquisition agreement with Merck, validating its platform and pipeline. Terns operates with a focused, agile team and a culture designed to accelerate development timelines in high-need therapeutic areas.

Therapeutic Areas